//
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)
Heart failure with preserved ejection fraction: from mechanisms to therapies
sST2 Predicts Outcome in Chronic Heart Failure Beyond NT−proBNP and High-Sensitivity Troponin T
Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Novel percutaneous interventional therapies in heart failure with preserved ejection fraction: an integrative review
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
Unexpectedly Low Natriuretic Peptide Levels in Patients With Heart Failure